Full Breakdown
Johnson & Johnson Q2 2026 Earnings Beat Expectations, Powered by Two Flagship Drugs
7/15/2026, 10:04:02 PM
Core Results
On July 15, 2026 Johnson & Johnson reported second-quarter revenue of $25.31 billion, up 6.6 % year over year and ahead of the consensus estimate of roughly $25.05 billion. Adjusted earnings per share were $2.90, surpassing the $2.85 forecast. The pharmaceutical segment generated $16.38 billion in sales, while the medical-technology unit posted $8.93 billion, slightly below analyst expectations.
Background & Context
The company’s long-standing immunology blockbuster Stelara lost patent protection in 2025, prompting a sharp decline of 55 % to $740 million in the quarter. J&J has been positioning Tremfya (psoriasis and inflammatory-bowel-disease) as the primary replacement, while Darzalex (multiple-myeloma) continues to drive oncology growth. The medical-device business, acquired through the 2022 $16.6 billion purchase of Abiomed, faced a 2 % drop in U.S. Impella heart-pump sales after a U.K. study questioned its use in high-risk coronary procedures.
Financial Highlights
| Segment | Q2 2026 Sales | YoY Change | Analyst Estimate |
|---|---|---|---|
| Pharmaceutical (Innovative Medicines) | $16.38 billion | +7.8 % (operational) | $16.10 billion |
| Medical-Technology | $8.93 billion | +4.5 % | $8.96 billion |
| Tremfya | $2.05 billion | +72.5 % | $1.85 billion |
| Darzalex | $4.21 billion | +18.9 % | $4.16 billion |
| Stelara | $0.74 billion | –55 % | $0.65 billion |
The company raised its 2026 sales guidance to $100.8 billion–$101.4 billion (midpoint $101.1 billion) and its adjusted earnings-per-share outlook to $11.60–$11.75 (midpoint $11.68), up from the prior ranges.
Executive Commentary (Official Statements & Responses)
Chief Financial Officer Joseph Wolk said the Impella slowdown is temporary and that a large data set expected in the first half of next year should address safety concerns. Executive Vice President Tim Schmid emphasized that overall procedure volumes remain stable despite broader industry warnings about surgical volume declines. Chairman and CEO Joaquin Duato highlighted that the raised outlook keeps J&J on track to exceed $100 billion in annual revenue for the first time in its 140-year history.
Market Reaction & Criticism
Although earnings beat, J&J’s shares fell roughly 2 % in pre-market trading, reflecting investor unease over the modest miss in medical-device sales and the heavy reliance—nearly 98 % of quarterly growth—on Tremfya and Darzalex. Analysts noted that a slip in either drug could pressure future results.
Conflicting Reports & Gaps
Revenue figures for the quarter appear as $25.31 billion (Reuters, CNBC) and $25.3 billion (The Globe and Mail), a negligible variance attributable to rounding.
Verbatim Quotes
- “When you have 28 platforms that generate ?at least $1 billion in revenue on an annual basis, we're not dependent on one asset.” — Joseph Wolk, CFO
- “Procedure volumes continue to be stable,” — Tim Schmid, Executive Vice President, MedTech
- “We have a big data set coming out probably in the first half of next year that should allay any fears,” — Joseph Wolk, CFO
- “CEO Joaquin Duato said the company is on pace for its 2026 goal of topping $100 billion in yearly revenue.” — Joaquin Duato, Chairman & CEO
- “0 billion quarter looks like a patent-cliff handoff, not a one-off pop.” — Analyst commentary (Finimize)
Why It Matters
J&J’s ability to offset the Stelara patent cliff with rapid Tremfya adoption demonstrates the importance of a diversified product portfolio. The strong oncology performance, led by Darzalex and newer agents such as Carvykti and Tecvayli, reinforces the company’s growth engine beyond legacy immunology drugs. However, the med-tech shortfall and concentration risk underscore the need for broader innovation to sustain the raised 2026 outlook.
